Jane Street Group LLC Sells 19,525 Shares of LivaNova PLC (NASDAQ:LIVN)

Jane Street Group LLC lowered its position in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 12.8% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 133,213 shares of the company's stock after selling 19,525 shares during the quarter. Jane Street Group LLC owned 0.25% of LivaNova worth $6,999,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Point72 DIFC Ltd lifted its position in shares of LivaNova by 75,799.6% in the third quarter. Point72 DIFC Ltd now owns 181,400 shares of the company's stock worth $9,531,000 after purchasing an additional 181,161 shares in the last quarter. Point72 Asset Management L.P. increased its stake in LivaNova by 62.7% in the 3rd quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company's stock valued at $109,914,000 after buying an additional 806,374 shares during the last quarter. Polar Asset Management Partners Inc. bought a new stake in LivaNova during the 3rd quarter worth about $1,949,000. Parkman Healthcare Partners LLC boosted its stake in shares of LivaNova by 19.5% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 101,729 shares of the company's stock worth $5,345,000 after buying an additional 16,570 shares during the last quarter. Finally, NFJ Investment Group LLC grew its holdings in shares of LivaNova by 104.1% in the 3rd quarter. NFJ Investment Group LLC now owns 96,400 shares of the company's stock valued at $5,065,000 after acquiring an additional 49,176 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

LIVN has been the topic of several analyst reports. StockNews.com lowered LivaNova from a "strong-buy" rating to a "buy" rating in a report on Saturday, November 16th. Baird R W upgraded LivaNova from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, September 17th. Mizuho decreased their target price on shares of LivaNova from $80.00 to $70.00 and set an "outperform" rating for the company in a research note on Thursday, October 31st. The Goldman Sachs Group started coverage on shares of LivaNova in a report on Friday, October 4th. They set a "buy" rating and a $65.00 target price on the stock. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $75.00 price target on shares of LivaNova in a research note on Monday, November 25th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $69.17.

Insiders Place Their Bets

In other news, Director Francesco Bianchi sold 1,250 shares of the business's stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total value of $63,737.50. Following the completion of the transaction, the director now directly owns 7,522 shares in the company, valued at approximately $383,546.78. The trade was a 14.25 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.27% of the company's stock.

LivaNova Stock Performance

LIVN stock traded down $0.61 during trading hours on Friday, hitting $51.50. 515,221 shares of the stock were exchanged, compared to its average volume of 610,064. LivaNova PLC has a 12 month low of $43.15 and a 12 month high of $64.47. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $2.80 billion, a P/E ratio of 122.62 and a beta of 0.98. The company has a 50-day simple moving average of $51.97 and a two-hundred day simple moving average of $51.49.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.